Stryker grabs Israeli brain aneurysm device company for $135M

Stryker ($SYK) has agreed to pay $135 million for Surpass Medical, an Israeli maker of next-generation medical devices to treat brain aneurysms.

The deal breaks down to $100 million upfront and an additional $35 million in milestone payments. Surpass is based in Tel Aviv, but maintains manufacturing and research and development operations in Florida, according to Stryker.

For Stryker, the deal gives it vital new technology with which to compete in the global neurovascular market. Surpass' NeuroEndoGraft uses flow-diversion stent technology to treat brain aneurysms. The NeuroEndoGraft has a CE mark and has had a limited commercial rollout. U.S. development plans are set to kick off by the end of the year with an IDE clinical trial scheduled to enroll patients.

Surpass was founded in 2005.

- read the release

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.